Stage III Renal Cell Cancer Recruiting Phase 2 Trials for Tyrosine (DB00135)

IndicationStatusPhase
DBCOND0028847 (Stage III Renal Cell Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02761057Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney CancerTreatment